ArticleJACC. Advances2025
Potential Impact of Colchicine on Atherosclerotic Cardiovascular Disease in the United States.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Temporal trends in the prescription of low-dose antithrombotic and anti-inflammatory therapies in Germany (2022-2024).Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Anti-Inflammatory Therapies in Acute Coronary Syndromes-A Review of Immunological, Genetic, and Clinical Challenges for Precision Medicine.Journal of clinical medicine · 2026Review
- Colchicine in Cardiovascular Disease: Evidence Structure, Clinical Efficacy, Safety, and Translational Positioning Across Cardiovascular Syndromes.International journal of molecular sciences · 2026Review
- Cardiovascular outcome trials (CVOTs) in cardiorenal metabolic medicine: a decade of transformative progress (2016-2026).Cardiovascular diabetology · 2026Review
- Screening for inflammation and treatment with colchicine in adults with known cardiovascular disease: an analysis of 13.5 million patients.Frontiers in medicine · 2026Article
- Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives.International journal of molecular sciences · 2025Review
- Personalized medicine for cardiovascular diseases: how next generation epigenetic technologies can contribute?Epigenomics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn the COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2) coronary artery disease trials, low-dose colchicine decreased the risk of major adverse cardiovascular events (MACEs) by 23% to 31% beyond statin therapy with a strong safety profile. The number of MACE potentially preventable by widespread colchicine use in the United States remains uncertain.
objectivesThe objective of this study was to estimate the current and potential impact of colchicine on cardiovascular outcomes.
methodsWe first calculated the number of new colchicine users with coronary artery disease before and after COLCOT and LoDoCo2 publication at an integrated health care system in southeastern New England from 2018 to 2023. Second, we estimated the number of potentially avoidable MACEs with widespread colchicine use using incidence rates and the relative risk reduction from the LoDoCo2 trial and the nationally representative National Health And Nutrition Examination Survey study.
resultsFrom January 2018 to December 2019 (before COLCOT and LoDoCo2 publication), the number of new colchicine users varied between 126 and 151 every 6 months. From January 2020 to June 2023, the number of new colchicine users increased from 141 to 181 every 6 months (<1% of adults with coronary artery disease at Mass General Brigham). Among the estimated 9.2 million adults with stable coronary artery disease on a statin in the United States, adding colchicine to standard medical management is estimated to prevent 226,000 MACE over a 3-year period.
conclusionsAdding colchicine to standard cardiovascular management may prevent 226,000 MACE in the United States over a 3-year period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.